Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06696261 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome

StatusRecruiting
PhasePhase 3
Started2025-02-27
View on ClinicalTrials.gov ↗

Amendment history

2026-01-15
Study Status v3
Primary completion date2026-06-01→2026-12-31
Completion date2026-08-01→2026-12-31
2025-06-01
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-01-01→confirmed 2025-02-27
Study sitesdetails revised at 18 of 18 sites
2024-11-20
Study Identification, Study Status, Outcome Measures v1
Secondary endpointsdetails revised at 8 of 10 entries
Study title-19 characters
A Phase III Clinical TrialStudy of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
2024-11-17
Original filing
The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are: 1. Based on the Response rate of postprandial distress syndrome participants, evaluate whether the efficacy of Lianxiaxiaopi Granules is superior to placebo. 2. Evaluate the efficacy of Lianxiaxiaopi Granules in improving symptom of postprandial distress syndrome. 3. Evaluating the safety of Lianxiaxiaopi Granules in postprandial distress syndrome participants.
Trial Details
NCT Number NCT06696261
Lead Sponsor Tasly Pharmaceutical Group Co., Ltd
Conditions Postprandial Distress Syndrome
Enrollment 342 participants
Start Date 2025-02-27
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-20